T-bet-regulated myeloid innate defense against Toxoplasma gondii

T-bet 调节的骨髓对弓形虫的先天防御

基本信息

项目摘要

Abstract Toxoplasma gondii is the causative agent of toxoplasmosis, and it is estimated to infect a third of the human population globally. T. gondii infection can result in serious complications including congenital toxoplasmosis of the fetus and death among immunocompromised individuals. Unfortunately, current regimens for T. gondii treatment show high rates of toxicity, and are only able to treat the acute stage of the parasitic infection. Therefore, there is an urgent need develop new medicines with specific efficacy against T. gondii. Host immunity against T. gondii is defined by a MyD88-dependent IL-12 response, which generates a CD4+ Th1- derived IFN-γ response necessary for host survival. The transcription factor T-bet is considered essential for the development and function of innate lymphoid cells (ILCs) and TH1s during T. gondii infection. T-bet is traditionally considered the master regulator of lymphocyte-derived interferon-gamma (IFN-γ) production. Yet, T-bet-independent ILC- and TH1-derived IFN-γ is insufficient for host immunity, demonstrating that IFN-γ alone is insufficient for host defense and that T-bet must be inducing an IFN-γ-independent anti-parasitic response. For instance, despite robust IFN-γ production, T-bet-deficient mice succumb to infection significantly faster than animals lacking lymphocytes, suggesting T-bet-expressing myeloid cells are required for host survival. Our objective is to define T-bet’s role in regulating myeloid cell-dependent immunity against T. gondii. Our preliminary findings have identified a unique T-bet expressing CD11c+MHCII- myeloid cell population that are critical for eliminating T. gondii. Based on these results, we hypothesize that T-bet expression in myeloid cells regulates pathogen clearance and host survival during T. gondii infection. To test our hypothesis, we will (i) determine the underlying mechanism(s) of T-bet in regulating myeloid cell-mediated defense against T. gondii (AIM 1) and (ii) define the molecular functions of T-bet-expressing myeloid cells in mediating host resistance against T. gondii (AIM 2). We will utilize unbiased T-bet reporter mice and cell-type-specific T-bet-deficient mice established in our lab, in combination with various molecular biology techniques, spectral cytometry, immunofluorescence, and single-cell RNA-sequencing. Together, these experiments will for the first time establish T-bet’s role in mediating myeloid cell-dependent host defense against T. gondii, thereby providing novel specific targets for therapeutic intervention.
摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

AMERICO HARRY LOPEZ-YGLESIAS其他文献

AMERICO HARRY LOPEZ-YGLESIAS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 31.5万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 31.5万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 31.5万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 31.5万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 31.5万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 31.5万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 31.5万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 31.5万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 31.5万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 31.5万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了